A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure

NCT00504608 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Infertility Implantation Failure

Interventions

DRUG: Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)

Sponsor

Merck KGaA, Darmstadt, Germany